Ablynx reports positive Ph2 data on RA drug; Astellas says Ph3 overactive bladder data points to improvement in symptoms;

@FierceBiotech: Biotechs pick up slack in antibiotics development. Article | Follow @FierceBiotech

@JohnCFierce: IMS expects US drug sales to grow from 0 to 3% per year to 2015, less than half the rate we've been seeing. Story | Follow @JohnCFierce

> Ablynx's rheumatoid arthritis drug ozoralizumab--which is licensed to Pfizer--worked in Phase II as it had hoped. Report

> Astellas announced the results of a pivotal Phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder. The data show mirabegron significantly improved key OAB symptoms--urinary incontinence (leakage of urine) and frequency of micturition (urination) compared with placebo. Astellas release

> Watson Pharmaceuticals reported new Phase II data showing that Rapaflo (silodosin) significantly reduced symptoms of moderate to severe chronic prostatitis/chronic pelvic pain syndrome. Watson release

> Astellas has completed its announced buyout of Perseid Therapeutics. Article

> Shares of Marina Biotech dropped to 25 cents after the company unveiled plans to raised $6.9 million through a new offering. Report

Pharma News

@FiercePharma: Forest shareholder demands CEO's resignation. Report | Follow @FiercePharma

> Generics, emerging markets to take over pharma growth. Article

> Pfizer looks to recoup billions in Neurontin sales. Story

> Can Merck/Roche hep C deal put Victrelis combo on top? Article

> Some Indian drugmakers break the generic mold. Report

> Nikkei says Nycomed buyout imminent; Takeda says no. Item

Drug Delivery News

> Consultant: Gene and cell therapy almost ready for prime time. Item

> 'Magnetofection' delivers DNA in experimental malaria vaccine. Article

> Microdosing project to help develop drugs for infants. Story

> More than one way to produce particles for inhaled drug delivery. Report

> Analyst: Fluzone Intradermal 'delivers the goods' in a patient-friendly system. Story

> 'Nanobot?" Maybe not, but cool, anyway. Item

Medical Device News

> Shire buys Advanced BioHealing for $750M. News

> Stryker to cut 142 jobs in Ireland. Report

> Medtronic's decision to end GPO contracts could aid rivals. Story

> Thulin tapped as 3M COO. Article

> Medtronic's CoreValve shows sustained quality of life improvements. Item

And Finally... The U.S. government is fighting efforts to destroy the last remaining stocks of smallpox, saying they're needed for further research on new medicines. Story

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.